Status | Study |
Active, not recruiting |
Study Name: Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis Condition: Whole Body Imaging Magnetic Resonance Imaging Neurofibroma Date: 2013-01-23 Interventions: Other: Additional imaging or surgery No specific intervention is necessary. If a suspicious lesion is di |
Active, not recruiting |
Study Name: Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) Condition: Neurofibromatoses Date: 2012-09-05 Interventions: Drug: Levulan (5-aminolevulinic acid) uptake. |
Completed |
Study Name: Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Condition: Neurofibromatosis Date: 2012-08-22 Interventions: Drug: Gleevec Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects |
Withdrawn |
Study Name: Proton Radiation Therapy for Spinal Tumors Condition: Nerve Sheath Tumors Neurofibroma Date: 2012-03-13 Interventions: Radiation: Proton Radiation for MPNST |
Suspended |
Study Name: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Condition: Neurofibromatosis NF1 Plexiform Neurofibromas Date: 2011-07-25 Interventions: Drug: Sutent®/Sunitinib Upon enrollment, subjects will receive Sutent® orally. Adults (Age > |
Completed |
Study Name: Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Condition: Neurofibromatosis NF1 Neurofibromas Date: 2011-01-11 Interventions: Drug: Tasigna Following enrollment each subject will initially receive Tasigna orally at 200 mg twice da |
Active, not recruiting |
Study Name: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Condition: Neurofibromatosis Neurofibromas Date: 2010-06-08 Interventions: Drug: Gleevec Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with |
Active, not recruiting |
Study Name: First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Condition: Cutaneous Neurofibromas Date: 2009-06-15 Interventions: Procedure: Erbium-YAG laser vaporization spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequen |
Active, not recruiting |
Study Name: Medical Treatment of "High-Risk" Neurofibromas Condition: Neurofibromatosis 1 Date: 2009-01-16 Interventions: Drug: Peg-Interferon alpha-2b |
Terminated |
Study Name: Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas Condition: Neurofibroma Date: 2008-07-14 Interventions: Drug: LS11 LS11 will be given as a one-time IV infusion over 3-5 minutes. |